Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for iZafe Group AB's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:M02 vs ISRG, BDX, MDLN: Total Payout Ratio Comparison
For the Medical Instruments & Supplies subindustry, iZafe Group AB's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iZafe Group AB Total Payout Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iZafe Group AB's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where iZafe Group AB's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iZafe Group AB (FRA:M02) has a Total Payout Ratio of 0.00 as of Aug. 17, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on iZafe Group AB and its competitors.
Is iZafe Group AB's Total Payout Ratio too high?
iZafe Group AB's current Total Payout Ratio is 0.00. Overall, iZafe Group AB has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does iZafe Group AB's Total Payout Ratio compare to ISRG and BDX?
iZafe Group AB's Total Payout Ratio of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Medical Devices & Instruments company?
A good Total Payout Ratio depends on the Medical Devices & Instruments industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on iZafe Group AB and its competitors. iZafe Group AB's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iZafe Group AB stock overvalued right now?
Based on GuruFocus' analysis, iZafe Group AB (FRA:M02) is currently considered Possible Value Trap. The stock's GF Value™ is €0.04, compared to a current price of €0.03 — trading 30% below its estimated fair value. The current Total Payout Ratio is 0.00. iZafe Group AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For iZafe Group AB (FRA:M02), the current Total Payout Ratio is 0.00 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iZafe Group AB (FRA:M02) Overvalued in 2026?
Based on GuruFocus' analysis, iZafe Group AB stock appears to be undervalued.
The current stock price of €0.03 is trading 30% below its estimated GF Value™ of €0.04.
GuruFocus considers iZafe Group AB to be Possible Value Trap.
Key valuation signals for FRA:M02:
Total Payout Ratio: 0.00
GF Value™: €0.04 vs. price of €0.03 (30% below fair value)
No single metric tells the full story. See the FRA:M02 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iZafe Group AB is a Developer of a digital medication dispensing system designed to enhance patient safety and reduce medication errors in home healthcare. The company offers a smart medication robot with automated dispensing and remote monitoring, enabling public and private healthcare providers in Sweden, the Nordics, and international markets, improved treatment adherence and reduced caregiver workload.
48GF Score
Get the complete analysis for FRA:M02
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M02 has been successfully added to your 
